Black Diamond Therapeutics (BDTX) Prepaid Assets (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Prepaid Assets came in at $4.9 million in Q2 2026, up 25.43% on a YoY basis from $3.9 million in Q2 2025, and up 3.8% quarter-over-quarter from $4.7 million in Q1 2026.
Analysis
Black Diamond Therapeutics (BDTX) Prepaid Assets (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported Prepaid Assets for 9 consecutive years, with $4.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets rose 25.43% year-over-year to $4.9 million; the trailing twelve-month figure through Jun 2026 stood at $4.9 million (up 25.43% YoY), and the FY2025 full-year result was $3.8 million, up 45.64% from the prior year.
- Prepaid Assets advanced to $4.9 million in Q2 2026 per BDTX's latest filing, from $4.7 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $8.6 million in Q1 2022 and bottomed at $2.6 million in Q4 2024.
- Historically, Prepaid Assets has averaged $4.4 million across 5 years, with a median of $3.8 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets tumbled 58.91% in 2023, then soared 45.64% in 2025.
- Over 5 years, Prepaid Assets stood at $4.9 million in 2022, then sank by 46.23% to $2.6 million in 2023, then slipped by 1.25% to $2.6 million in 2024, then jumped by 45.64% to $3.8 million in 2025, then rose by 29.04% to $4.9 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $4.9 million, $4.7 million, and $3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.89 Mn |
| Mar 31, 2026 | 4.71 Mn |
| Dec 31, 2025 | 3.79 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | 3.28 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 3.78 Mn |
| Mar 31, 2024 | 3.61 Mn |
| Dec 31, 2023 | 2.63 Mn |
| Sep 30, 2023 | 2.79 Mn |
| Jun 30, 2023 | 3.47 Mn |
| Mar 31, 2023 | 4.61 Mn |
| Dec 31, 2022 | 4.90 Mn |
| Sep 30, 2022 | 6.80 Mn |
| Jun 30, 2022 | 7.67 Mn |
| Mar 31, 2022 | 8.57 Mn |
| Dec 31, 2021 | 5.92 Mn |
| Sep 30, 2021 | 6.54 Mn |